Aliskiren/valsartan

Drug Profile

Aliskiren/valsartan

Alternative Names: Rasival; Valturna

Latest Information Update: 24 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Branched-chain amino acids; Fumarates; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Hypertension
  • No development reported Acute coronary syndromes

Most Recent Events

  • 20 Jul 2012 Withdrawn for Hypertension in USA (PO)
  • 17 May 2012 No development reported - Phase-II for Acute coronary syndromes in Canada (PO)
  • 17 May 2012 No development reported - Phase-II for Acute coronary syndromes in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top